EYPT NASDAQ
EyePoint Pharmaceuticals, Inc.
1W: -10.2%
1M: -32.1%
3M: -77.5%
YTD: -81.4%
1Y: -74.8%
3Y: -60.2%
5Y: -72.3%
$3.25
+0.02 (+0.62%)
Weekly Expected Move ±13.3%
$2
$3
$3
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships3
As Filer
counterparties named
2
As Counterparty
mentioned by others
1
Rel. Types
2021-08-23
Earliest Filing
2021-12-10
Latest Filing
partner: 3
Counterparties (Filed by EYPT)
3 relationshipsCompanies named in EYPT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| ImprimisRx | — | partner | Partner assuming full responsibility for U.S. sales and marketing of DEXYCU and absorbing the majority of EyePoint's com | 2021-12-10 | View |
| Harrow Health | HROW | partner | Parent company of ImprimisRx, the partner assuming responsibility for DEXYCU sales and marketing. | 2021-12-10 | View |
| Cowen and Company, LLC | — | partner | Underwriter representing the underwriters in the public offering of common stock and pre-funded warrants. | 2021-11-19 | View |
Mentioned As Counterparty
2 mentionsOther companies that named EYPT in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| HROW HARROW HEALTH, INC. | partner | Pharmaceutical company expanding commercial alliance for DEXYCU | 2021-12-09 | View |
| WHWK Aerpio Pharmaceuticals, Inc. | supplier | Aerpio sold patents and patent applications for razuprotafib and Tie2 antibodies to EyePoint in exchange for a $450,000 | 2021-08-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-10 | Other Events; Exhibits | View | |
| 2026-08-17 | Other Events; Exhibits | View | |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-07-30 | Other Events; Exhibits | View | |
| 2026-07-17 | Material Agreement; Exhibits | Agreement | View |
| 2026-06-22 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-14 | Other Events; Exhibits | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-04-13 | Other Events; Exhibits | View | |
| 2026-03-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-02 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-08 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-11-19 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-17 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-10-14 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-29 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR